← ANALYST RATINGS · TIPRANKS
Trevi Therapeutics (TRVI): analyst forecast and price target
Analyst consensus
Strong Buy10 Buy0 Hold0 Sell
Ratings of 10 analysts in the last 3 months12-month forecast
Based on 10 price targets given in the last 3 months, the average target is $29.00, the highest $40.00, the lowest $23.00. The average is +144.1% from the last price of $11.88.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 → $12.00−7.7% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $12.00 → $11.50−4.2% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $12.50 → $12.00−4.0% | Hold | +1.0% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $12.00 → $11.50−4.2% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $12.00 → $11.50−4.2% | Hold | −3.2% | Reiterated | 15.10.26on TipRanks 06:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $12.00 → $11.50−4.2% | Sell | −3.2% | Downgrade | 15.10.26on TipRanks 06:05 | — | |
| Name not given | — | $36.00 | Buy | +203.0% | Reiterated | 06.10.26on TipRanks Oct 7 08:35 | −4.5%next day −0.1% · 5 days −6.6% | ↗ |
| Brandon Folkes★★★★★★★★★★#10500 · hits 39% · avg −1.1% | H.C. Wainwright | $24.00 | Buy | +102.0% | Reiterated | 21.09.26on TipRanks 13:55 | −2.0%next day +2.4% · 5 days −2.3% | ↗ |
| Debanjana Chatterjee★★★★★★★★★★#121 · hits 68% · avg +45.6% | JonesTrading | $24.00 → $28.00+16.7% | Buy | +135.7% | Assigned | 13.08.26on TipRanks 15:35 | +1.7%next day +1.9% · 5 days +2.5% | ↗ |
| Judah Frommer★★★★★★★★★★#2495 · hits 56% · avg +5.3% | Morgan Stanley | $23.00 | Buy | +93.6% | Assigned | 10.08.26on TipRanks Aug 7 08:20 | −0.6%next day −3.8% · 5 days −0.7% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $23.00 | Buy | +93.6% | Reiterated | 07.08.26on TipRanks 17:15 | −3.8%next day +0.3% · 5 days +3.9% | ↗ |
| Ryan Deschner★★★★★★★★★★#506 · hits 69% · avg +41.7% | Raymond James | $40.00 | Buy | +236.7% | Reiterated | 07.08.26on TipRanks 09:40 | −0.6%next day −3.8% · 5 days −0.7% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $31.00 | Buy | +160.9% | Initiated | 07.08.26on TipRanks 09:15 | −0.6%next day −3.8% · 5 days −0.7% | ↗ |
| Leland Gershell★★★★★★★★★★#2332 · hits 40% · avg +6.2% | Oppenheimer | $24.00 → $25.00+4.2% | Buy | +110.4% | Reiterated | 07.08.26on TipRanks 08:20 | −0.6%next day −3.8% · 5 days −0.7% | ↗ |
| Annabel Samimy★★★★★★★★★★#421 · hits 51% · avg +19.3% | Stifel Nicolaus | $30.00 | Buy | +152.5% | Reiterated | 07.08.26on TipRanks 08:15 | −0.6%next day −3.8% · 5 days −0.7% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $25.00 → $30.00+20.0% | Buy | +152.5% | Reiterated | 06.08.26on TipRanks Aug 7 08:55 | −0.6%next day −0.6% · 5 days −3.1% | ↗ |
| Kaveri Pohlman★★★★★★★★★★#1640 · hits 40% · avg +12.9% | Clear Street | $21.00 → $29.00+38.1% | Buy | +144.1% | Reiterated | 07.05.26on TipRanks 18:00 | +2.4%next day +2.4% · 5 days −2.3% | ↗ |
| Roanna Ruiz★★★★★★★★★★#9351 · hits 46% · avg −0.3% | Leerink Partners | $13.00 → $16.00+23.1% | Buy | +34.7% | Reiterated | 18.11.25on TipRanks Nov 20 09:45 | +0.5%next day −2.8% · 5 days −1.8% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Trevi Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $29.00 at a price of $14.32 (+102.5%); now: $29.00 at $11.88 (+144.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 18 | 7 | 8 | 7 | 8 | 7 |
| Buy | 3 | 2 | 5 | 7 | 7 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 11.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.13 (from $-0.17 to $-0.11). Last quarter: $-0.11.
Best top-analyst consensus in the sector · Healthcare
About Trevi Therapeutics
- CEO: Jennifer L. Good
- Employees: 34
- 195 Church Street, New Haven, CT, 06510, US
- www.trevitherapeutics.com
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions. This orally administered, extended-release formulation of nalbuphine is currently undergoing Phase IIb/III clinical trials for chronic pruritus (severe itching) and persistent cough experienced by patients with idiopathic pulmonary fibrosis. Trevi Therapeutics also possesses a licensing agreement with Endo Pharmaceuticals Inc., granting it the rights to develop and market products containing nalbuphine hydrochloride in various formulations. Established in 2011, the company maintains its corporate headquarters in New Haven, Connecticut.
Data from the stock’s TipRanks forecast page, read 56 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗